Loading clinical trials...

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service | Clinical Trials | Clareo Health

COMPLETED

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal

NCT03223012•AbbVie

View on ClinicalTrials.gov

Summary

This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed with crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (SpA) or psoriasis (Pso) according to the treating physician
•Adalimumab was started within 1 month prior to study enrollment
•Adalimumab was introduced based on current clinical practice criteria (i.e., the prescription of adalimumab was clearly separated from the decision to include the participants in this study)
•No prior record of adalimumab treatment
•Adalimumab was administered according to product label
•Naïve or previously experienced with biologic treatment
•Participant is able and willing to provide written authorization to disclose and use personal health information (informed consent), and to agree that data will be collected and provided to AbbVie
•Initiated the AbbVie care program within the first month after starting adalimumab.

Exclusion Criteria

•Definitive discontinuation of adalimumab before being proposed to participate in the study
•Participated in any clinical experimental research within the 2 months prior to enrollment
•Pregnant or breastfeeding female participants
•Participant not able or not willing to comply with the requirements of this study protocol.

Locations (15)

Instituto Portugues De Reumatologia /ID# 205963

Lisbon, Lisbon District, Portugal

Centro Hosp de Lisboa Central /ID# 205698

Lisbon, Lisbon District, Portugal

Centro Hospitalar Lisboa Ocidental, EPE /ID# 201328

Lisbon, Lisbon District, Portugal

Centro Hospitalar Lisboa Ocidental, EPE /ID# 201330

Lisbon, Lisbon District, Portugal

CCA Braga - Hospital de Braga /ID# 201322

Braga, Portugal

CCA Braga - Hospital de Braga /ID# 201323

Braga, Portugal

CCA Braga - Hospital de Braga /ID# 201324

Braga, Portugal

Hospital Santo Antonio dos Cap /ID# 205700

Lisbon, Portugal

Centro Hospitalar Lisboa Norte, EPE /ID# 201335

Lisbon, Portugal

Centro Hospitalar Lisboa Norte, EPE /ID# 201336

Lisbon, Portugal

Key Dates

Start Date

November 15, 2017

Primary Completion Date

February 28, 2019

Completion Date

February 28, 2019

Last Updated

February 24, 2020

Enrollment

116

ACTUAL participants

Conditions

Crohn's DiseaseUlcerative Colitis (UC)Rheumatoid Arthritis (RA)Psoriatic ArthritisPsoriasisAnkylosing Spondylitis (AS)Non-radiographic Axial Spondyloarthritis

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

View study

RECRUITINGPHASE2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

Plant-Based Diet for Patients With Rheumatoid Arthritis

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease